Prenatal screening for trisomy II trimester of pregnancy (biochemical screening II trimester of pregnancy, the "triple test» II trimester) — a set of research being undertaken to pregnant women in order to assess the risk of fetal anomalies — Down syndrome (trisomy of chromosome 21), Edwards syndrome (trisomy 18) neural tube defects (NTDs).
What indicators are included in the "triple test» II trimester?
- Human chorionic gonadotropin (hCG, beta-hCG);
- Alpha-fetoprotein (AFP);
- Free estriol
What are the indications for "triple test"?
Prenatal screening for trisomy II trimesters of pregnancy is carried to all pregnant women. Specific indications include:
- women over the age of 35 years;
- the presence of a child (or a history — of the fetus aborted pregnancy) with genetically confirmed Down syndrome and other chromosomal diseases, congenital malformations;
- hereditary disease in the immediate family;
- radiation exposure or other harmful effects on one's spouse before conception.
At what stage of pregnancy is carried II trimester prenatal screening?
Optimal timing of the survey — from 16 to 18 weeks of pregnancy.
What should be the preparation for the "triple test» I trimester?
For this study, you must have the results of fetal ultrasound made no earlier than one week prior to analysis.
What are the dates of performance analysis?
1 day.
How are the results of the "triple test» I trimester?
The results of calculating the risk of chromosomal abnormalities are not the basis for a diagnosis, and are an indication for further special methods of investigation on the advice of the obstetrician-gynecologist.